The agreement was made between Onset Dermatologics and Lupin's American subsidiary, Lupin Pharmaceuticals which grants exclusive rights to Lupin for marketing Locoid Lotion, a corticosteroid used in topical treatment of mild to moderate Atopic Dermatitis in patients 3 months of age and older.
Stating that it will help expand the market for Locoid Lotion, Onset Dermatologics President Bob Moccia said, "This partnership will give pediatricians greater opportunity to utilize Locoid lotion in their patients while Onset maintains its focus on promoting Locoid to the dermatology community. We are confident that Locoid will continue to be the most prescribed mid-potency steroid brand in the U.S."
Source-Medindia
No comments:
Post a Comment